Sulfasalazine: A Review of its Pharmacological Properties and Therapeutic Efficacy in the Treatment of Rheumatoid Arthritis

Drugs

Volumn 50, Issue 1, 1995, Pages 137-156

  Rains, Christopher P ^a   Noble, Stuart ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; GOLD SALT; HYDROXYCHLOROQUINE; LOBENZARIT; MESALAZINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ACETYLATOR PHENOTYPE; BLOOD CELL COUNT; BLOOD DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOPATHOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG DISEASE; LYMPHOID TISSUE; MALE FERTILITY; MALE INFERTILITY; META ANALYSIS; MORNING STIFFNESS; ORAL DRUG ADMINISTRATION; PREGNANCY; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIUM; TERATOGENESIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; DOSAGE FORMS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FERTILITY; HUMAN; MALE; METHOTREXATE; PREGNANCY; PREGNANCY COMPLICATIONS; SULFASALAZINE;

EID: 0028998289     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550010-00009     Document Type: Article

References (134)

1. Rheumatoid arthritis. Pathophysiology and implications for therapy
2. Immunological aspects of rheumatic disease: implications for treatment
3. Rheumatic Disorders
4. Role of T-cell antigen receptors in rheumatic disease
5. Sulphasalazine and related drugs in rheumatoid arthritis
6. Salazopyrin in rheumatoid arthritis
7. Sulphasalazine in rheumatoid arthritis
8. Reclassification of antirheumatic agents: how and why
9. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis
10. Which component of sulphasalazine is active in rheumatoid arthritis
11. Sulphasalazine therapy in rheumatoid arthritis: qualitative changes in lymphocytes and correlation with clinical response
12. Preliminary report. Methylsulphasalazine in rheumatoid arthritis
13. The use of suppressive agents for the treatment of rheumatoid arthritis
14. Effect of sulphasalazine on antibody response to oral antigen
15. Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid-arthritis
16. Evidence of a local intestinal immunomodulatory effect of sulfasalazine in rheumatoid arthritis
17. HML1 antigen expression on synovial fluid lymphocytes of RA patients and its regulation by sulfasalazine, sulfapyridine, 5 ASA and methotrexate [abstract]
18. Inhibitory effects of sulfasalazine and related compounds on Superoxide production by human polymorphonuclear lymphocytes
19. Circulating inhibitor bound elastase in patients with ankylosing spondylitis and rheumatoid arthritis and the influence of sulphasalazine treatment
20. In vitro immunomodulatory effects of sulfasalazine and its metabolites
21. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis
22. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine
23. Production of interleukin-6 by monocytes isolated from rheumatoid arthritis patients receiving second-line drug therapy
24. Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine
25. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs
26. Is the beneficial effect of sulfasalazine due to inhibition of synovial neovascularization
27. Alteration of thiol and Superoxide dismutase status in rheumatoid arthritis treated with sulphasalazine [see comments]
28. Association of enhanced Superoxide generation by neutrophils with low Superoxide scavenging activity of the peripheral blood, joint fluid, and their leukocyte components in rheumatoid arthritis: effects of slow-acting anti-rheumatic drugs and disease activity
29. Effect of sulphasalazine on gastrointestinal microflora and on mucosal heat shock protein expression in patients with rheumatoid arthritis
30. Effects of sulphasalazine on faecal flora in patients with rheumatoid arthritis: a comparison with penicillamine
31. Sequential study of bacterial antibody levels and faecal flora in rheumatoid arthritis patients taking sulphasalazine
32. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid
33. Clinical pharmacokinetics of slow-acting antirheumatic drugs
34. The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis
35. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease
36. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis
37. Sulphasalazine treatment during breat feeding
38. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis
39. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis
40. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis
41. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment
42. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study
43. Sulfasalazine in rheumatoid arthritis. A double-blind, placebo-controlled trial [published erratum appears in Arthritis Rheum 1987 Apr; 30 (4): 459]
44. Sulfasalazine in early rheumatoid arthritis
45. The natural history of active rheumatoid arthritis over 3–6 months — an analysis of patients enrolled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo
46. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
47. Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis
48. Optimizing the assessment of disease activity during treatment with anti-rheumatoid drugs
49. Validity of single variables and indices to measure disease activity in rheumatoid arthritis
50. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis
51. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis
52. Sulphasalazine: a safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate
53. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate
54. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis
55. Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial
56. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine
57. A double blind comparative study between salazosulfapyridine enteric-coated tablets (PJ-306) and lobenzarit disodium (CCA) [in Japanese]
58. Sulphasalazine versus penicillamine in the treatment of rheumatoid arthritis
59. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial
60. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period
61. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials
62. Outcome of second line therapy in rheumatoid arthritis
63. Assessing the progression of joint damage in rheumatoid arthritis
64. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis
65. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis
66. Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-up [letter]
67. Sulphasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate
68. Disease modifying drugs for rheumatoid arthritis: yesterday’s treatment today or today’s treatment tomorrow
69. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis
70. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomised open cliniucal trial in rheumatoid arthritis patients resistant to sulphasalazine therapy
71. Combination therapy with methotrexate and sulfasalazine therapy in patients with rheumatoid arthritis-tolerance of therapy [letter]
72. Improving the response to gold or D-penicillamine by addition of sulphasalazine. A pilot study in 25 patients with rheumatoid arthritis
73. Sulphasalazine alone or in combination with D-penicillamine in rheumatoid arthritis
74. The use of sulphasalazine and azathioprine in combination to treat rheumatoid arthritis [letter]
75. Triple DMARD therpy for rheumatoid arthritis is well tolerated [abstract]
76. Adverse reactions to sulfasalazine: the British experience [see comments]
77. Sulphasalazine hepatotoxicity: lack of a hypersensitivity response
78. Sulfasalazine-induced fulminant hepatic failure
79. Pulmonary infiltrates and skin pigmentation associated with sulfasalazine
80. Sulfasalazine-induced pulmonary disease
81. Acute alveolitis and sulphasalazine in rheumatoid arthritis [letter]
82. Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis
83. Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis
84. Clinical and serological autoimmune dysfunction in patients treated with sulphasalazine [abstract no. 100]
85. Sulphasalazine induced autoimmune syndrome
86. Sulfasalazine induced lupus in rheumatoid arthritis
87. Sulfasalazine induced systemic lupus erythematosus in a patient with rheumatoid arthritis [letter]
88. Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis
89. Sulphasalazine-induced systemic lupus erythematosus in a patient with Sjogren’s syndrome
90. Drug-related lupus in a patient with rheumatoid arthritis under sulfasalazine treatment
91. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods
92. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years
93. Sulphasalazine in rheumatoid arthritis: long term tolerability in 423 patients monitored for 2 to 15 years (abstract No. 578)
94. Sulphasalazine in rheumatoid arthritis: desensitising the patient with a skin rash
95. Desensitization to sulphasalazine in patients with arthritis
96. Rheumatoid arthritis-II: treatment
97. Does low dose desensitization affect the toxicity of sulphasalazine (SASP) in the treatment of rheumatoid arthritis (RA)? [abstract no. 186]
98. A one-year, open, prospective tudy of sulfasalazine in the treatment of rheumatoid arthritis: adverse reactions and clinical response in relation to laboratory variables, drug and metabolite serum levels, and acetylator status
99. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study
100. Profound leucopenia with Salazopyrin EN [letter; comment] [see comments]
101. Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis
102. Sulphasalazine induced aplastic anaemia
103. Fatal neutropenic enterocolitis associated with sulphasalazine therapy for rheumatoid arthritis
104. Fatal agranulocytosis with sulfasalazine therapy in rheumatoid arthritis
105. Leucopenia during sulphasalazine treatment for rheumatoid arthritis
106. Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy [see comments]
107. Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy [see comments]
108. The risk of sulfasalazine- and mesalazine-associated blood disorders
109. Slow acting drug therapy of rheumatoid arthritis: treatment duration and side effect profile [abstract no. 197]
110. Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone
111. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages
112. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice
113. A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs
114. Optimisation of antirheumatic drug treatment in pregancy
115. Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution
116. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis
117. Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis
118. Rheumatoid arthritis-I: clinical features and diagnosis
119. Models of combination therapy with disease-modifying antirheumatic drugs. Early, aggressive therapy for rheumatoid arthritis: concerns, descriptions, and estimate of outcome
120. The long-term outcome of treating rheumatoid arthritis, results after 20 years
121. Course and prognosis of early rheumatoid arthritis
122. The gold standard in rheumatoid arthritis [editorial]
123. Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient
124. Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis
125. Disease-modifying antirheumatic drugs in rheumatoid arthritis: current concepts
126. Methotrexate and misoprostil for abortion at 57–63 days gestation
127. Methotrexate and misoprostol vs misoprostol alone for early abortion
128. Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent
129. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheiumatic disease
130. Does sulphasalazine cause folate deficiency in rheumatoid arthritis
131. Minimal compliance with the Department of Health recommendation for routine folate prophylaxis to prevent neural tube defects